Under a tenth of individuals who could benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it publishes its first recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer access to this class of drugs.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to widespread availability to the jabs that can aid individuals in losing substantial weight, notes the organization.
Skinny Jab Scarcity
Even in the present most optimistic case, the supply of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges nations and manufacturers to widen access, through approaches like licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in several countries in 2026.
The Way Weight-Loss Jabs Operate
The injections mimick a body's own hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake.
People usually begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Studies points to users may put most of the weight back on after a year of stopping the medication, because their usual hunger return.
To be above a healthy weight elevates your likelihood for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.
